Immutep Limited PRRUF

PRRUF Company Overview

Immutep Limited (NASDAQ: IMMP; ASX: IMM) is a clinical-stage biotechnology company focused on developing immunotherapies for cancer and autoimmune diseases. The company’s core scientific platform centers on lymphocyte activation gene-3 (LAG-3), an immune checkpoint molecule involved in regulating T-cell function. Immutep operates within the oncology and immuno-oncology industries, with its primary value drivers tied to the development, licensing, and commercialization potential of LAG-3-based therapeutics. Its lead product candidate, eftilagimod alpha (efti), is designed as a soluble LAG-3 protein that stimulates antigen-presenting cells to enhance immune responses, particularly in combination with checkpoint inhibitors and chemotherapy.

The company traces its origins to research conducted by French immunologist Frédéric Triebel, who discovered LAG-3 and founded the precursor entity that later evolved into Immutep. Over time, Immutep transitioned from a broader immunology platform into a focused immuno-oncology developer with clinical programs targeting solid tumors and hematologic cancers. The company differentiates itself through a substantial intellectual property portfolio surrounding LAG-3 biology and through its positioning as one of the earlier companies to clinically develop both agonist and antagonist applications linked to the LAG-3 pathway.